Researchers from the UCLA Health Jonsson Comprehensive Cancer Center have published new research in the journal JAMA Oncology demonstrating that chemotherapy plus high doses of radiation are a safe and effective treatment for people with locally advanced non-small cell lung cancer (NSCLC) that is not suitable for surgery. The Jonsson…

Originally Aired: May 18, 2023Time: 8:00 am PT, 11:00 am ET, 17:00 CET VIEW NOW SHORTLY To be implemented in the clinic, tests must be validated and approved through a regulatory process. Coverage and procedures for mutation types vary among the many available tests. There are various methods for EGFR mutation detection,…

Cancer genetic testing company NeoGenomics and Eli Lilly and Company, through its Loxo Oncology unit, have entered into a sponsored partnership program that will see Lilly provide molecular testing for eligible patients with metastatic non-small cell lung cancer (NSCLC). The Lilly Lung Cancer Sponsored Testing Program will employ the NeoTYPE…

About 15 percent of lung cancers are classified as small cell lung cancer. Recent studies have indicated that four major subtypes of small cell lung cancer exist, yet approaches to tailor treatment of these subtypes have not yet become standard of care. Now, scientists outline new findings “MYC Drives Temporal…

Broadcast Date: September 19, 2024Time: 8:00 am PT, 11:00 am ET, 17:00 CET REGISTER Early diagnosis and swift treatment are critical to changing the lung cancer landscape. Aligned with this goal, blood-based testing is a valuable tool to support clinical decision-making from diagnosis through monitoring. In this webinar, Dr. Gary Pestano will…

A lung cancer patient at University College London Hospitals (UCLH) was the first to receive a novel mRNA-based vaccine designed to prime the immune system to fight cancer cells very specifically. The BioNTech immunotherapy (BNT116) is being studied in a worldwide lung cancer trial. The NIHR UCLH Clinical Research Facility…

New research from the Brigham and Women’s Hospital investigators has provided new details on different levels of cardiac risks for patient who receive radiation therapy to treat non-small cell lung cancer (NSCLC). The study, published in JACC: CardioOncology, leveraged artificial intelligence (AI) to uncover how different radiation doses impact specific…

AstraZeneca (AZ) announced Thursday that its supplemental Biologic License Application has been granted priority review by the U.S. Food and Drug Administration (FDA) for the treatment of limited-stage small cell lung cancer (LS-SCLC). The regulatory decision is based on results of the ADRIATIC Phase III clinical trial in patients with…

Lung adenocarcinoma is the most common form of lung cancer in the world, and genetic markers are needed to help predict the prognosis of this disease and improve treatment outcomes. Using gene databases and patient data, a team from the Tongji Medical School and the Huazhong University of Science and…

There may be new hope in the hunt for reliable ways to detect cancer early on, an area where traditional diagnostic methods often prove inadequate. By analyzing cell-free DNA (cfDNA) end-motifs, AI can now distinguish between cancer patients and healthy individuals, according to a research article published in npj Precision…

Too many cancer treatment approaches turn into a game of Whac-A-Mole in which genetic resistance among cancer cells becomes amplified. To play a new, more winnable game, researchers are using genetic circuits to realize evolution-guided anticancer therapies in which diverse forms of resistance are thwarted. Researchers at Penn State created…

Targeted treatment for non-small cell lung cancer (NSCLC) sometimes fails to work, even in patients who have never smoked. The reason, new research suggests, hangs on two mutations in the EGFR and TP53 genes. Patients with mutations in these two genes are more likely to have mixed intra-patient tumor responses…

LORBRENA (Pfizer’s lorlatinib) has delivered the longest progression-free survival (PFS) ever reported in advanced ALK-positive, non–small cell lung cancer (NSCLC). The company reported 60% of patients treated with LORBRENA were alive without disease progression after five years, according to data from the phase III CROWN trial data presented during the…

A Phase III study from The University of Texas MD Anderson Cancer Center has revealed that combining perioperative immunotherapy with chemotherapy significantly improves outcomes for patients with resectable early-stage non-small cell lung cancer (NSCLC). The research, published in the New England Journal of Medicine, demonstrates that administering nivolumab both before…

Researchers from the University of California (UC), San Diego, have developed a novel AI platform that can generate individual drug compounds capable of inhibiting multiple molecular targets at once. They used it to synthesize 32 new drug candidates for cancer. The POLYGON platform, short for POLYpharmacology Generative Optimization Network, uses…